Background-Overexpression of stromal cell-derived factor-1 in injured tissue leads to improved end-organ function. In this study, we quantify the local trophic effects of mesenchymal stem cell (MSC) stromal cell-derived factor-1 release on the effects of MSC engraftment in the myocardium after acute myocardial infarction. Methods and Results-Conditional cardiac myocyte CXCR4 (CM-CXCR4) null mice were generated by use of tamoxifen-inducible cardiac-specific cre by crossing CXCR4 floxed with MCM-cre mouse. Studies were performed in littermates with (CM-CXCR4 null) or without (control) tamoxifen injection 3 weeks before acute myocardial infarction. One day after acute myocardial infarction, mice received 100 000 MSC or saline via tail vein. We show ␣-myosin heavy chain MerCreMer and the MLC-2v promoters are active in cardiac progenitor cells. MSC engraftment in wild-type mice decreased terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling positive CM (Ϫ44%, PϽ0.01), increased cardiac progenitor cell recruitment (100.9%, PϽ0.01), and increased cardiac myosin-positive area (39%, PϽ0.05) at 4, 7, and 21 days after acute myocardial infarction, respectively. MSC in wild-type mice resulted in 107.4% (PϽ0.05) increase in ejection fraction in comparison with 25.9% (PϭNS) increase in CM-CXCR4 null mice. These differences occurred despite equivalent increases (16%) in vascular density in response to MSC infusion in wild-type and CM-CXCR4 null mice. Conclusions-These data demonstrate that the local trophic effects of MSC require cardiac progenitor cell and CM-CXCR4 expression and are mediated by MSC stromal cell-derived factor-1 secretion. Our results further demonstrate and quantify for the first time a specific paracrine mechanism of MSC engraftment. In the absence of CM-CXCR4 expression, there is a significant loss of functional benefit in MSC-mediated repair despite equal increases in vascular density. (Circulation. 2012;126:314-324.)
S tem cell-based therapies have demonstrated that there is significant potential to improve myocardial healing after acute myocardial infarction (AMI). [1] [2] [3] [4] [5] Adult stem cell therapy is currently moving forward for the prevention and treatment of cardiac dysfunction in patients with ischemic heart disease. Although these studies are moving forward, the mechanisms of benefit remain undefined despite significant efforts. Confounding all studies to date is the fact that multiple potential mechanisms are involved, and experimental manipulations in 1 pathway often cause confounding effects on other pathways.
Clinical Perspective on p 324
Stromal cell-derived factor-1 (SDF-1)-CXCR4 axis has been shown to be critical in tissue repair in multiple organ systems including the skin, eye, kidney, brain, and heart. 6 -10 The expression level of SDF-1 elevated at 1 hour after myocardial infarction and returned to baseline by 7 days and remains downregulated through 30 days after myocardial infarction (MI). 11 The lack of myocardial SDF-1 expression beyond 7 days post-AMI is a likely explanation for the lack of efficacy of intracoronary infusion of bone marrow-derived stem cells in the LATETIME trial. 12 Furthermore, overexpression of SDF-1 has been shown to improve tissue repair through the recruitment of tissue-specific and bone marrowderived stem cells. 13 However, as yet undefined is the precise role of end-organ CXCR4 in tissue repair in response to SDF-1 expression and/or response to stem cell-based repair. We have demonstrated that cardiac myocytes upregulate CXCR4 (CM-CXCR4) expression 36 to 48 hours after AMI. 8 Attempts to determine the precise role of the SDF-1:CXCR4 axis in tissue repair have been confounded because systemic inhibition of SDF-1:CXCR4 binding also results in stem cell mobilization of the bone marrow. 14, 15 Thus, to date, inhibiting tissue SDF-1:CXCR4 binding has been studied in the setting of greater stem cell mobilization. To begin to address these mechanisms, we have recently generated the conditional CM-CXCR4 null mouse. 16 We have further demonstrated that there is no phenotypic difference between control and CM-CXCR4 null mouse following AMI. Mesenchymal stem cells (MSC) are known to express SDF-1 8, 11 ; thus, the goal of this study is to determine the role of MSC-induced SDF-1 expression and CM-CXCR4 MSC-mediated cardiac repair.
Materials and Methods

Generation of CM-CXCR4 Null Mouse
We have recently published the generation and characterization of the CM-CXCR4 null mouse. 8 It was generated by using a CXCR4 f/f mouse (kind gift from Yong-Rui Zou, Feinstein Laboratory for Hematopoiesis, New York, NY) in a C57Bl/6 strain with the MerCreMer mouse (from The Jackson Laboratories) for inducible CM-CXCR4 null mouse. The MerCreMer mouse has cre induced by a tamoxifen-inducible cardiac-specific promoter and has been used extensively to induce recombination in cardiac myocytes and possibly cardiac stem cells. 17, 18 Mice received tamoxifen (40 mg/kg) daily for 5 days starting 4 weeks before left anterior descending artery (LAD) ligation to achieve cardiac-specific cre expression. The cardiac-specific cre expression leads to excision of Exon 2 of the CXCR4 gene, rendering the CM-CXCR4 null. The administration of tamoxifen led to a transient decline in cardiac function that was back to baseline 3 weeks later. 19 Therefore, all LAD ligations in this study were performed 3 weeks after the tamoxifen injection and in animals with recovered cardiac function. Our previous data demonstrated that cardiac myocytes in the infarct border zone begin to express CM-CXCR4 36 to 48 hours after MI. 8 Therefore, immunofluorescent staining and Western blot were performed to quantify CXCR4 deletion 2 days post-MI. Our results demonstrate that the administration of tamoxifen to these mice leads to a Ϸ90% decrease in CXCR4 protein in infarct and infarct border zone. 16 The Animal Research Committee approved all animal protocols. Mice were housed with free access to food and water in an American Association for Accreditation of Laboratory Animal Care-approved animal.
MSC Preparation and Delivery
Six-week-old green fluorescent protein (GFP) mouse was euthanized and the hindlimbs were removed. Femurs were carefully cleaned of adherent soft tissue, and bone marrow was flushed into a 50-mL Falcon with flush medium (Alpha Medium with 2 g/L NaHCO 3 , 10% horse serum, 10% fetal bovine serum, 1% L-glutamine, 1% penicillin-streptomycin). The cells were filtered through a 70-m nylon mesh filter followed by centrifugation for 5 minutes at 260 g and washed with PBS. The washed cells were plated in flush medium and incubated at 37°C. Nonadherent cells were removed by replacing the medium after 24 hours. The cells were cultured in a monolayer at 37°C and 5% CO 2 and medium was refed every 3 to 4 days. When cells reached 80% confluence, adherent cells was detached after incubation with 0.05% trypsin and 2 mmol/L EDTA (Invitrogen) for 5 minutes. Cells were depleted of CD45 ϩ , CD34 ϩ cells by negative selection with primary PE-conjugated antibodies: mouse anti-CD45 (BD Biosciences, San Diego, CA) and mouse anti-CD34 antibodies (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). PE-positive cells were negatively selected by using the EasySep PE selection kit according to the manufacturer's instructions (Stem Cell Technologies, Vancouver, BC, Canada). MSCs were replaced in medium and were subsequently passaged until passage 6. One day after LAD ligation, mice underwent echocardiography to confirm anterior wall MI. Animals with an ejection fraction Ͻ50% received 100 000
MSCs that were suspended in 100 L of PBS or 100 L of PBS alone was infused via tail vein injection.
LAD Ligation
Anterior wall MI was induced in mice as described. 20 On brief, animals were endotracheal intubated and ventilated with room air at 100 breaths per minute by using a rodent ventilator (Harvard Apparatus). Sternotomy was performed, and the proximal LAD was identified by use of a surgical microscope (Leica M500) after retraction of the left atrium and ligated with 7-0 prolene. Blanching and dysfunction of the anterior wall verified LAD ligation. After LAD ligation, the animals were evaluated with echocardiography or euthanized at different time points for organ harvest (heart) and staining.
Echocardiography
Two-dimension echocardiography was performed using a 15-MHz linear array transducer interfaced with a Sequoia C256 (Acuson) as preciously described. 20 In brief, 3 days before LAD ligation, and 4 days, 7 days, and 21 days after LAD ligation, as well, left ventricle (LV) dimensions were quantified by digitally recorded 2-dimensional clips and M-mode images in a short-axis view from the mid-LV just below the papillary muscles to allow for consistent measurements from the same anatomic location in different mice. Measurements were made by 2 independent blinded researchers off-line with the use of ProSolv echocardiography software. Each measurement in each animal was made from 3 randomly chosen m-Mode clips of 5 recorded by observers blinded to the strain of the mice. Dimensions were measured between the anterior wall and posterior wall from the short-axis view just below the level of the papillary muscle.
Immunostaining
Four days and 21 days after LAD ligation, mice were anesthetized and perfusion fixed with 10% phosphate-buffered formalin at physiological pressures. Fixed hearts were embedded in paraffin and serially cut at 4 m from the apex to the level just below the coronary artery ligation site. Antigen retrieval was performed by use of 10 mmol/L sodium citrate buffer (pH 6.0) and incubated with 1% normal blocking serum in PBS for 60 minutes to suppress nonspecific binding of IgG. Four days after AMI, tissue was stained for GFP (1:1000, Abcam, Inc, San Francisco, CA) to calculate GFPϩ MSCs. Three weeks after AMI, tissue was stained to measure vessel density and percentage of cardiac myosin-positive area in the infarct zone. Negative control with no fluorescent probe was used in immunostaining to control the autofluorescene.
MSC Homing Following MSC Infusion
Four days post-MI, tissue was prepared as described above for immunostaining. The number of GFPϩ cells was quantified in the infarct zone by independent blinded researchers across a minimum of 4 sections and 12 fields obtained from the mid-LV per animal.
TUNEL Assay for Assessment of Apoptotic Cell Death
Terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) was performed to detect apoptotic nuclei by using terminal deoxynucleotidyltransferase-mediated in situ fluoresceinconjugated, dUTP nick end-labeling technique according to the manufacturer's protocol (Roche, Indianapolis, IN). The sections were incubated with mouse monoclonal antibody (Abcam, Inc, San Francisco, CA) to recognizing cardiac myosin heavy chain to specifically recognize apoptotic cardiomyocytes. The fluorescence staining was viewed with a confocal laser-scanning microscope. The number of apoptotic cells with TUNEL-positive nuclei was counted by 2 independent observers blinded to treatment group and expressed as a percentage of total myocyte population. TUNEL-positive nuclei in 1000 nuclei within 4 to 5 cells from the infarct border zone from 5 different sections (4000 -5000 nuclei total) were obtained from the mid-LV.
Percentage of Cardiac Myosin-Positive Area Measurement
Three weeks post-AMI, tissue was prepared as described above for immunostaining. Slides were stained with the mouse anti-CM heavy-chain primary antibody (Abcam, Inc, San Francisco, CA) and then with goat anti-mouse IgG Alexa Fluor 594 (Molecular Probes, Carlsbad, CA) and mounted with aqueous mounting medium (Vectashield Mounting Medium with 4,6-diamidino-2-phenylindole (DAPI), H-1200; Vector Laboratories, Burlingame, CA). Five fields in the infarct zone were randomly selected for each sample and measured by an observer blinded to treatment group with ImagePro Plus software (Media Cybernetics) as previously described. 8, 21 
Myocardial Infarct Size Measurement
Four days and 21 days after LAD ligation, mice were anesthetized and perfusion fixed with 10% phosphate-buffered formalin at physiological pressures. Fixed hearts were embedded in paraffin and serially cut at 4 m from the apex to the level just below the coronary artery ligation site. Alternating sections were stained with Masson trichrome. The infarcted area was measured by planimetry with use of computer-assisted image analysis software Image-Pro Plus (Media Cybernetics). Parameters were calculated using the following equation: % infarct sizeϭepicardial infarct length/epicardial LV circumferencesϫ100.
Vessel Density Measurement
Three weeks post-AMI, tissue was prepared as described above for immunostaining. Sections were stained with fluorescein-conjugated isolectin (Vector Laboratories), which stains endothelium, and rhodamine-conjugated wheat germ agglutinin (Vector Laboratories), which labels myocyte membranes as previously described. 22 Five to 10 randomly selected fields for each sample were imaged at 630ϫ by use of confocal microscopy and vessel density within the infarct border zone was measured. All quantitative evaluations were performed with ImagePro Plus software (Media Cybernetics).
Isolation of Cardiac Progenitor Cells From Mouse Hearts
Cardiac progenitor cells (CPCs) were isolated from mouse hearts in different groups 7 days post-MI as described previously. 23 In brief, infarct zones of hearts were digested with use of 0.1% collagenase B and 2.4 U/mL dispase II (Roche Molecular Biochemicals) containing 2.5 mmol/L CaCl 2 at 37°C for 45 minutes. Cells then were filtered through 30-m filters, washed in Hanks balanced salt solution (Invitrogen) containing 2% fetal calf serum and 10 mmol/L HEPES and were lysed with red blood cell lysing buffer. After washing with PBS, cells were resuspended in 2ϫ10 6 nucleated cells/mL. Cells were fixed with 4% paraformaldehyde and then were incubated with antibodies against the mouse CD16/32, APC rat anti-mouse CD117, V450 rat anti-mouse CD45 (BD Biosciences). Flow cytometry was performed on a FACSCalibur (BD Biosciences). 20 Data were analyzed with FlowJo software. The percentage of Ckitϩ/CD45Ϫ cells in the infarction zone 7 days post-MI was calculated. To investigate whether ␣-myosin heavy chain (␣MHC)-MerCreMer promoter is activated in endogenous CPC, CPCs were isolated from CM-CXCR4 null mouse hearts 3 weeks after tamoxifen injection. After fixed with 4% paraformaldehyde and treated with 0.1% triton, the cells were incubated with APC rat anti-mouse CD117, V450 rat anti-mouse CD45 (BD Biosciences), anti-␤-gal (Cell Signaling), and ␣-MHC (Abcam). Immunostaining and flow cytometry were performed to investigate the recombination in CPC. Spleen cells were used as control.
SDF-1 mRNA and Protein Expression
Four and 7 days after LAD ligation, the hearts were perfused with saline and infarcted left ventricles were cut at a level just below the ligation. The RNA was harvested by use of TRIzol, and cDNA was synthesized with use of SuperScript VILO cDNA synthesis kit from Invitrogen. The real-time polymerase chain reaction for SDF-1 and 18S was performed by use of TaqMan primers on Applied Biosystems 7500 Real-Time PCR System. To identify the source of SDF-1, we performed immunofluorescence staining with paraffin-embedded tissue 4 days and 3 weeks post-AMI. Samples were stained for GFP (1:1000, Abcam, Inc, San Francisco, CA) and SDF-1 (1:50, Santa Cruz, Inc, Santa Cruz, CA). Negative control with no fluorescent probe was used in immunostaining to control the autofluorescene.
Statistical Analysis
Data are analyzed with SigmaPlot Statistics and presented as meanϮSEM. Comparisons between 2 groups were made with a 2-tailed Student t test ( Figure 1 ). Comparisons among multiple groups were made with 2-way ANOVA followed by the Tukey post hoc analysis (see Table and Figures 2 through 6). No statistics were required for data in Figure 7 . Three-way ANOVA was used for Figure 8 . All differences were considered statistically significant at PϽ0.05 levels.
Results
Role of CM-CXCR4 Expression on MSC Homing Following Cell Therapy
To investigate the role of CM-CXCR4 on MSC homing following cell therapy, 100 000 GFPϩ MSCs (isolated from GFP mouse, passage 6) were suspended in 100 L of PBS and infused via tail vein injection 24 hours after AMI. Three days after infusion (4 days post-AMI), the hearts were harvested and embedded in paraffin. Sections were stained with an antibody to GFP, and the number of GFPϩ cells was quantified in the infarct zone by independent blinded observers ( Figure 1A and 1B) . Although we have observed a 33% decrease in SDF-1 mRNA expression in CM-CXCR4 null mice in comparison with the control mice 3 days after LAD ligation by real-time polymerase chain reaction, 16 no significant differences in MSC engraftment were observed between groups with or without CM-CXCR4 expression ( Figure 1 ) suggesting that the absence of CM-CXCR4 expression and the degree of decrease in SDF-1 expression in the CM-CXCR4 null mice do not alter MSC recruitment to the heart after AMI.
Role of CM-CXCR4 Expression on Cardiac Myocyte Preservation Following Cell Therapy
SDF-1:CXCR4 binding has been shown to induce cell survival through phosphorylation of AKT and the STAT3 pathways. 24, 25 To investigate the role of CM-CXCR4 expression on cardiac myocyte preservation following MSC deliv- ery, the number of TUNELϩ cardiac myocytes in the infarct border zone 4 days after AMI was quantified. As seen in Figure 2 , in the absence of MSC infusion, there was no difference in the number of TUNELϩ cardiac myocytes in mice with or without CM-CXCR4 expression. However, consistent with our previous results in the rat, 8 the infusion of MSC 1 day after AMI led to a significant 44% reduction in TUNELϩ cardiac myocytes (PϽ0.01 in comparison with the control group). Interestingly, in the absence of CM-CXCR4 expression, the decrease in cardiac myocyte apoptosis was blunted by almost 50% (23%) and significantly greater than control mice treated with MSC.
Role of CM-CXCR4 Expression on Infarct Size and Percentage of Cardiac Myosin-Positive Area Following Cell Therapy
To evaluate if reduced cardiomyocyte apoptosis 4 days after AMI is sufficient to decrease cardiac damage, we measured the cardiac myosin-positive area within the infarct zone by immunofluorescence 21 days after AMI. We observed that, in the absence of stem cell therapy, CM-CXCR4 expression does not alter the number of surviving cardiac myocytes within the infarct zone. However, in response to MSC infusion 1 day after AMI, we observed a significant increase in cardiac myosin-positive area within the infarct zone (43.9%). This increase in cardiac myosin-positive area in response to MSC infusion was not observed in the CM-CXCR4 null mice (Figure 3 ).
Role of CM-CXCR4 Expression on Ventricular Remodeling and Cardiac Function Following Cell Therapy
Consistent with our previous findings, in the absence of stem cell therapy, CM-CXCR4 expression does not alter LV function and LV remodeling 21 days after AMI (Table and Figure 4 ). 8, 16 The infusion of MSC 1 day after AMI led to a significant improvement in ejection fraction and decreased systolic and diastolic LV internal dimension in comparison with controls animals that received saline. MSC therapy also significantly increased interventricular septal thickness in systole and diastole without change the systolic and diastolic thickness of the LV posterior wall in control mice; however, in the absence of CM-CXCR4 expression, there was no significant improvement in cardiac function or remodeling (ejection fraction, systolic LV internal dimension, diastolic LV internal dimension, interventricular septal thickness in diastole, and interventricular septal thickness in systole) in response to MSC infusion (Table and Figure 1 ). These data demonstrate that CM-CXCR4 plays a critical role in post-MI ventricular remodeling and cardiac function following MSC engraftment.
Role of CM-CXCR4 Expression on Vascular Density Following Cell Therapy
To investigate if CM-CXCR4 expression may affect vascular density following MSC infusion, we evaluated vascular density 21 days after AMI. Immunofluorescence with use of wheat germ agglutinin and isolectin was used to identify and quantify the vasculature within the infarct zone. A significant increase in the number of capillaries and small arterioles was observed in WT and CM-CXCR4 null mice that received MSC 21 days after AMI ( Figure 5A and 5B ).
Role of CM-CXCR4 Expression on CPC Recruitment Following Cell Therapy
We investigated whether the ␣MHC-MerCreMer promoter and/or the MLC-2v-cre promoters are activated in CPC. We quantified promoter activity by immunostaining and flow cytometry by crossing the cre-inducible ␤-gal mouse with the ␣MHC-MerCreMer and the MLC-2v-cre mice. Our data showed that the ␣MHC-MerCreMer and MLC-2v promoters are activated in endogenous CPC ( Figure 7A through 7C) . To further investigate whether there is evidence of an extracardiac progenitor cell whose recruitment we could be affecting through the downregulation of CXCR4, we performed flow cytometry on the cellular population isolated from the spleen and did not observe any significant evidence of ␤-galϩ cells in those mice that received tamoxifen as seen in Figure 7B .
To determine if promoter activation has functional consequences in CPC we quantified CPC recruitment following AMI with and without MSC infusion. We found that MSC engraftment led to a significant increase of CPC recruitment (100.9%, PϽ0.01) in the heart of WT mice 7 days after AMI and that CPC recruitment in response to MSC was significantly decreased to 55.4% in CM-CXCR4 null mice ( Figure  6A and 6B ).
Role of MSC Infusion on Myocardial SDF-1 Expression
We wanted to confirm that MSC engraftment in the myocardium led to increased and sustained SDF-1 expression. Therefore, we quantified SDF-1 mRNA levels in the infarct zone 4 and 7 days after LAD ligation by real-time polymerase chain reaction. As seen in Figure 8A , SDF-1 levels decreased Ϸ30% to 40% in all groups between days 4 and 7 with a trend toward Ϸ50% and Ϸ30% greater SDF-1 mRNA expression in those animals that received MSC at 4 and 7 days after 
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AMI, respectively. To identify the source of SDF-1, we performed immunofluorescence staining with paraffinembedded tissue 4 days and 3 weeks post-AMI. We observed SDF-1 expression in MSCs, cardiac myocytes, and other non-MSC cells 4 days post-MI ( Figure 8B ). However, SDF-1 expression was only detected in engrafted MSC and not cardiac myocytes 21 days post-MI (data not shown).
Discussion
With the use of our novel model of CM-CXCR4 null mice, for the first time, we were able to specifically dissect the effects of MSC SDF-1 expression on end-organ tissue repair.
In this study, we demonstrated a critical role for CPC and cardiac myocyte CXCR4 expression on MSC-mediated cardiac repair. Most importantly, we observed that inhibiting CPC and cardiac myocyte response to SDF-1 by deletion of CXCR4 blocked significant improvement in cardiac function despite equivalent levels of MSC engraftment (Figure 1 ) and a significant increase in vascular density within the injured myocardium ( Figure 5 ).
Our study also demonstrates that the ␣MHC-MerCreMer and MLC-2v promoters are activated in endogenous CPC ( Figure 7A through 7C) . Moreover, we confirmed our earlier observations that MSC engraftment leads to a significant increase in CPC recruitment 13 in WT mice, that was significantly blunted in CM-CXCR4 null mice (100.9% versus 55.4%) in the infarcted heart 7 days after AMI. Our data demonstrate that increases in SDF-1 expression following ischemic injury results in increased bone marrow and cardiac stem/progenitor cell homing to the myocardium that is responsible, at least in part, for the benefits associated with stem cell therapy. There is increasing recognition that CXCR4 expression by cardiac myocytes is responsible for ischemic preconditioning 26 and cardiac myocyte preservation following cell therapy. 8 Previous studies have suggested an important role for the SDF-1:CXCR4 axis in stem cell-based repair; however, the strategies for dissecting the importance of CM-CXCR4 have to date been confounded because CXCR4 and SDF-1 null mice are not viable. Inhibiting CXCR4:SDF-1 binding with CXCR4 antagonists (ie, AMD3100) is confounded because it leads to stem cell mobilization from the bone marrow leading to increased bone marrow-derived endothelial progenitor cell recruitment. 27 Our previous findings showed that myocyte CXCR4 has no role in ventricular remodeling after MI in the absence of cell therapy 16 owing to the mismatch in timings of peaks of SDF-1 and CXCR4. These results were confirmed again in our current study. Our study demonstrates prolonged SDF-1 expression in mice that received MSC infusion with trends toward greater SDF-1 levels in WT animals that received MSC. Interestingly, we found SDF-1 expression in MSCs and non-MSC cells 4 days post-MI. The cells that are responsible for SDF-1 expression include injured cardiomyocytes, 25 cardiac progenitor cells, 25 endothelial cells, 28 and smooth muscle cells. 28 However, SDF-1 was detected in MSC and not cardiac myocytes 21 days post-MI. This observation supports the concept that SDF-1 release by MSC leads to the recruitment of CXCR4 ϩ CPC that may further release SDF-1. 29 That we observed no difference in vascular density between WT and CM-CXCR4 null mice suggests that CPCs do not have a significant role in the vascular response to MSC engraftment after AMI.
Our current and previous data demonstrate that activation of SDF-1/CXCR4 signaling leads to preservation of cardiac myocytes and improvement in cardiac function. 8 This antiapoptotic effect of SDF-1:CXCR4 binding has previously been shown to be mediated by the phosphoinositide 3-kinase/ Akt signaling pathway. 30 Our previous data showed that CXCR4 signaling does not enhance cardiomyocyte hypertrophy. 16 Our current data indicate that CM-CXCR4 expression plays an important role on CPC recruitment, cardiac myocyte preservation, left ventricular remodeling, and function following cell therapy for MI. It was recently reported that the overexpression of CM-CXCR4 by gene transfer showed a negative inotropic effect. 31 Cardiac myocyte CXCR4 expression may act as a marker of an injured or dysfunctional cardiac myocyte, potentially leading to hibernation of cardiac myocytes to minimize energy-dependent properties and further injury. Our study shows that, in the absence of CM-CXCR4 expression, there is a significant decrease in cardiac myocyte survival in response to MSC infusion. The decreased cardiac myocyte survival within the infarct zone leads to inhibition of significant improvements in cardiac function and remodeling 21 days after AMI in response to MSC infusion. Taken together these data indicate that an important mechanism associated with the benefits of MSC engraftment is the delivery of SDF-1 (through MSC infusion and MSC-induced endogenous CPC recruitment) to CXCR4positive cardiac myocytes. Our current study further proves that myocardial CXCR4 is necessary for improved cardiac function in the presence of MSC after MI. In summary, our study directly quantifies the impact of a specific stem cell paracrine factor on cardiac myocyte survival and left ventricular remodeling and function after AMI. Our findings demonstrate that myocardial CXCR4 plays a critical role in myocardial response to MSC engraftment through the improvement of the CPC recruitment and the inhibition of myocyte apoptosis post-MI. These data demonstrate that increase in vascular density is not sufficient to improve ventricular remodeling and function; increasing cardiac myocyte survival during infarct expansion is necessary. These data demonstrate that the significant mode of action of MSCs is the local release of SDF-1 to block end-organ cell death, and suggest that inducers of early CXCR4 could be efficacious, 26 and that expression or prolongation of myocardial SDF-1 expression 8 could be strategy for minimizing tissue damage in the setting of acute injury. Further studies are needed to define the effects of CXCR4 in specific cell populations. Such studies could directly impact the development of clinical targets for improving cardiac function after MI and chronic heart failure.
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